Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump.
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...
Brazil's data protection watchdog ANDP has banned Tools for Humanity from offering payment for iris scanning in the country.
OpenAI CEO Sam Altman is under fire for suggesting that artificial intelligence will upend societal norms after President ...
OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
OpenAI has recently released its first AI agent, Operator. But how is it different from the ChatGPT platform? Let's find out.